The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase 1 participants to evaluate the safety
Pfizer Inc.: U.S. FDA Accepts for Priority Review Pfizer s Application for TicoVac (Tick-borne Encephalitis Vaccine)
4 transmitted to humans through the bite of an infected tick,
5 and less frequently by ingestion of unpasteurized milk or milk products from infected animals.
4 It may initially be mistaken for summer flu,
18,19 but can be a serious condition with possible long-term consequences.
4,19 More than 1 in 3 people can have long-term effects that last months or years
including cognitive changes, muscle weakness or permanent paralysis,
4,19 and in rare cases (0.5-2%; up to 20% in Russia), people may die.
20,21 TBE can affect people of all ages who come into contact with ticks whenever they do outdoor activities in countries where ticks infected with TBE are prevalent.
Share:
Solensia is the first injectable monoclonal antibody (mAb) licensed for alleviation of pain associated with osteoarthritis (OA) in cats
Solensia works as a monthly treatment targeting Nerve Growth Factor (NGF), a key player in OA pain
European Commission Marketing Authorization for a similar product in dogs, Librela
®,
was received in November 2020
Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia
® (frunevetmab), a new feline osteoarthritis treatment to alleviate pain. Osteoarthritis in cats is a very prevalent condition
1, existing in 40% of cats, and may generate pain and limit a cat s comfort and quality of life if not treated.
Zoetis Inc.: Zoetis Receives European Commission Marketing Authorization for Solensia (frunevetmab), a New Therapy for Feline Osteoarthritis Pain
Solensia works as a monthly treatment targeting Nerve Growth Factor (NGF), a key player in OA pain
European Commission Marketing Authorization for a similar product in dogs, Librela
,
was received in November 2020 Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia (frunevetmab), a new feline osteoarthritis treatment to alleviate pain. Osteoarthritis in cats is a very prevalent condition
1, existing in 40% of cats, and may generate pain and limit a cat s comfort and quality of life if not treated.
Pfizer : Event Announcement | MarketScreener marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.